Effects of topical amphotericin B on expression of cytokines in nasal polyps

Seung-Heon Shin1, Mi-Kyung Ye

  • 1Department of Otolaryngology, School of Medicine, Catholic University of Daegu, Daegu, South Korea. hsseung@cu.ac.kr

Acta Oto-Laryngologica
|March 17, 2005
PubMed
Abstract

Insights

Topical antifungal treatment for chronic rhinosinusitis (CRS) showed potential in reducing inflammatory cytokines in nasal polyps. Further research is needed to confirm the efficacy of amphotericin B in managing CRS inflammation.

Area of Science:

  • Otolaryngology
  • Immunology
  • Infectious Diseases

Background:

  • Chronic rhinosinusitis (CRS) is a prevalent chronic disease with poorly understood origins.
  • Fungal presence is increasingly implicated in the chronicity and inflammation of CRS.
  • Targeting fungal elements with topical antifungals may offer a therapeutic strategy for CRS.

Purpose of the Study:

  • To investigate the impact of intranasal antifungal irrigation on inflammatory cytokine levels in nasal polyps.
  • To assess the potential of topical amphotericin B in modulating the inflammatory milieu of CRS.

Main Methods:

  • Nasal polyps were obtained from patients before and after 4 weeks of treatment.
  • Treatment groups included topical amphotericin B (100 mg/l and 50 mg/l) and normal saline irrigation.
  • Cytokine levels (IL-5, IL-8, interferon-gamma, RANTES) in polyp homogenates were quantified using ELISA.

Main Results:

  • Nasal polyps exhibited elevated levels of IL-5, IL-8, and RANTES compared to normal turbinates.
  • A trend towards decreased IL-5 levels was observed after topical treatment, though not statistically significant.
  • Both amphotericin B and saline irrigation influenced nasal polyp cytokine expression.

Conclusions:

  • Topical amphotericin B and nasal saline irrigation impact cytokine expression in nasal polyps.
  • Intranasal irrigation strategies may play a role in managing the inflammatory processes associated with CRS.
  • The study suggests a potential benefit of topical antifungal therapy in CRS, warranting further investigation.